3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
10
Phase 2
5
Phase NA
2
Phase 3
2
Phase 4
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Renal Cell
9
Sarcoma
4
Neoplasms
2
Neoplasm Metastasis
2
Patient Preference
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Kidney Neoplasms
1
Hemangiosarcoma
1
Fallopian Tube Neoplasms
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
Prednisone
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
atezolizumab
7
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
pazopanib
×
Clear all
NCT01235962
2020-11-23
PROTECT
Novartis
Phase 3
Completed
1,538 enrolled
27 charts
NCT01064310
2017-04-17
PISCES
Novartis
Phase 3
Completed
169 enrolled
16 charts